-
Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe [Elektronski vir] : a Central European Cooperative Oncology Group analysisČufer, Tanja, 1955- ...Background. Treatment of non-small cell lung cancer (NSCLC) improved substantially in the last decades. Novel targeted and immune-oncologic drugs were introduced into routine treatment. Despite ... accelerated development and subsequent drug registrations by the European Medicinal Agency (EMA), novel drugs for NSCLC are poorly accessible in Central and Eastern European (CEE) countries. Material and Methods. The Central European Cooperative Oncology Group conducted a survey among experts from 10 CEE countries to provide an overview on the availability of novel drugs for NSCLC and time from registration to reimbursement decision in their countries. Results. Although first-generation epidermal growth factor receptor tyrosine kinase inhibitors were reimbursed and available in all countries, for other registered therapies - even for ALK inhibitors and checkpoint inhibitors in first-line - there were apparent gaps in availability and/or reimbursement. There was a trend for better availability of drugs with longer time from EMA marketing authorization. Substantial differences in access to novel drugs among CEE countries were observed. In general, the availability of drugs is not in accordance with the Magnitude of Clinical Benefit Scale (MCBS), as defined by the European Society for Medical Oncology (ESMO). Time spans between drug registrations and national decisions on reimbursement vary greatly, from less than 3 months in one country to more than 1 year in the majority of countries. Conclusion. The access to novel drugs for NSCLC in CEE countries is suboptimal. To enable access to the most effective compounds within the shortest possible time, reimbursement decisions should be faster and ESMO MCBS should be incorporated into decision making.Vir: The oncologist [Elektronski vir]. - ISSN 1549-490X (Vol. 25, iss. 3, Mar. 2020, str. e598-e601)Vrsta gradiva - e-članek ; neleposlovje za odrasleLeto - 2020Jezik - angleškiCOBISS.SI-ID - 2048592241
Avtor
Čufer, Tanja, 1955- |
Ciuleanu, Tudor |
Berzinec, Peter |
Galffy, Gabriela |
Jakopović, Marko |
Jassem, Jacek |
Jovanovic, Dragana |
MIhaylova, Zhasmina |
Ostoros, Gyula |
Thallinger, Christiane |
Zemanova, Milada |
Zielinski, Christoph
Teme
Carcinoma, non-small cell lung |
Therapy |
Europe |
Eastern Europe |
Drug therapy |
Europe |
Eastern Europe |
Nedrobnocelični karcinom pljuč |
Terapija |
Evropa |
Vzhodna Evropa |
Terapija z zdravili |
Evropa |
Vzhodna Evropa |
nedrobnocelični rak pljuč |
zdravljenje |
nova zdravila |
Srednja Evropa |
Jugovzhodna Evropa |
non-small cell lung cancer |
treatment |
novel drugs |
Central Europe |
Southeastern Europe
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|---|
Čufer, Tanja, 1955- | 12179 |
Ciuleanu, Tudor | |
Berzinec, Peter | |
Galffy, Gabriela | |
Jakopović, Marko | |
Jassem, Jacek | |
Jovanovic, Dragana | |
MIhaylova, Zhasmina | |
Ostoros, Gyula | |
Thallinger, Christiane | |
Zemanova, Milada | |
Zielinski, Christoph |
Izberite prevzemno mesto:
Prevzem gradiva po pošti
Obvestilo
Gesla v Splošnem geslovniku COBISS
Izbira mesta prevzema
Mesto prevzema | Status gradiva | Rezervacija |
---|
Prosimo, počakajte trenutek.